Skip to main content
. Author manuscript; available in PMC: 2014 Jun 9.
Published in final edited form as: Nat Med. 2013 Nov 7;19(11):1389–1400. doi: 10.1038/nm.3388

Figure 4.

Figure 4

Efficacy of targeted therapies in cancer treatment. Response rates and impact on progression-free survival vary widely among targeted therapies. The orange oval represents the reported response rates and progression-free survival for EGFR TKIs in EGFR-mutant lung adenocarcinoma (adapted from Supplementary Table 1). Imatinib targets BCR–ABL, has a ~95% response rate and has turned CML into a chronic disease for many patients165. All-trans retinoic acid targets the PML–RAR fusion protein and may cure acute promyelocytic leukemia (APML) when given in combination with chemotherapy166. For solid tumors such as melanoma and lung cancer, targeted therapies have a lower response rate and less of an impact on progression-free survival167–169. GIST, gastrointestinal stromal tumors.